Personalized anti-thrombotic management of patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1 — a statement of the ESC Working Group on Cardiovascular Pharmacotherapy and ESC Council on Stroke [corrected]
- PMID: 33496325
- DOI: 10.1093/eurheartj/ehaa1081
Personalized anti-thrombotic management of patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1 — a statement of the ESC Working Group on Cardiovascular Pharmacotherapy and ESC Council on Stroke [corrected]
Erratum in
-
Erratum to: Personalized anti-thrombotic management of patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1 - a statement of the ESC Working Group on Cardiovascular Pharmacotherapy and ESC Council on Stroke.Eur Heart J. 2021 Aug 7;42(30):2954. doi: 10.1093/eurheartj/ehab455. Epub 2021 Jul 16. Eur Heart J. 2021. PMID: 34269377 No abstract available.
Comment on
-
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC.Eur Heart J. 2021 Feb 1;42(5):373-498. doi: 10.1093/eurheartj/ehaa612. Eur Heart J. 2021. PMID: 32860505 No abstract available.
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
